semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bone Metastases Patients who sign the informed consent form and are willing to complete the study according to the plan; 2. Age 18-80 years old; 3. ECOG score ≤ 2 points; 4. CT shows that the main lesion is considered to be ground glass nodular lung cancer; 5. Preoperative examination CEA <5ng/ul 6. There are no bone related symptoms 7. There is no obvious absolute surgical contraindication for preoperative examination  History of bone related diseases. 2. History of other kinds of cancer
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Orofacial Pain When pain attacks, the average unilateral orofacial pain severity >=5 point measured by a 10-point VAS scale Patient with trigeminal neuralgia can be diagnosed according to Trigeminal neuralgia: New classification and diagnostic grading for practice and research (Neurology, 2016) Other kinds of orofacial pain can be diagnosed based on the patient's symptoms Provide written inform consent Free of any other diagnosed psychological conditions  with any other diseases such as cardiovascular, renal, neurological, digestive, hepatic, respiratory disease Pregnancy or lactation Participation in a clinical study that may interfere with participation in this study History of or current tobacco, alcohol use Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study Unable to provide written informed consent due to any reason
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-110.0,  Quality of Life Parastomal Hernia permanent active sigmoideostomy, transverseostomy, jejunostomi or ileostomy temporary active sigmoideostomy, transverseostomy, jejunostomi or ileostomy  age younger than 18 years stoma closure at follow-up death
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Wound Heal Healthy patients above 18 years old with mirror image vertical or mesioangular bilateral impacted mandibular third molars  Missing second molars or indicated for extraction (un-restorable and remaining roots) Patients under immunosuppressant and patients with acute infection Patients who fail to attend for follow-up appointments
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Periodontal Attachment Loss Periodontal Bone Loss Periodontal Diseases a full-mouth plaque score (FMPS) 25 and a full-mouth bleeding score (FMBS) 26 < 20% at the time of surgery to have at least 20 teeth at least 1 tooth exhibiting vertical bone loss detected by radiographic examination (alveolar crest level [ ACL] bottom of the defect [ BD] distance = Bone defect depth [ BDD]) ≥ 4 mm and a probing pocket depth (PPD) ≥ 5mm when evaluated 12 weeks after phase I non surgical therapy [ scaling and root planing ( SRP)]  no systemic diseases no medications affecting periodontal status during the previous 6 months not pregnant or lactating non-smoker no periodontal therapy in the 2 previous years no inadequate endodontic treatment, no dental mobility
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Renal Osteodystrophy Patients with reduced renal function: -≥ 18 years estimated Glomerular Filtration Rate (eGFR) ≤ 20 ml/min/1,73m2 PTH < 150 pg/ml or PTH > 300 pg/ml  ongoing malignancy Allergy towards tetracyclin Pregnancy Control Group: -≥ 18 years eGFR >= 60 ml/min under examination for c prostata Prostatic Specific Antigen (PSA) total <40 µg/l Former kidney disease ionized calcium or PTH outside normal range Known metabolic bone disease treatment with anticoagulants
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Bariatric Surgery Candidate Male Hypogonadism Muscle Loss Eligible for bariatric surgery according to the Danish national (i.e. aged 18-60 years, BMI >35 kg/m2 with specific secondary disease or BMI >40 kg/m2 with significant health issues assessed by the multidisciplinary bariatric team) [42] Caucasian men Total testosterone < 12.0 nmol/l No contraindications for testosterone treatment  Previously diagnosed with prostate, mammae or liver cancer. Any other cancer within the last 5 years Hypersensitivity to the active substance or to any of the excipients in Nebido® Symptomatic heart disease NYHA >2 Recently thromboembolic disease <3 months PSA >4.0 ug/l or PSA>3.0 ug/l and lower urinary tract symptoms Disability that severely affect the ability to perform exercise training EVF > 52%
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Peripheral Neuropathic Pain Radiculopathy Lower Back Pain History, symptoms and clinical findings consistent with painful radiculopathy in lower extremity(ies) ("probable" or "definite") for at least 3 months, with or without lower back pain. The pain in the extremity(ies) must dominate Understand Norwegian or Swedish language (written and spoken) Usual pain intensity ≥ 3.5 / 10 (NRS 0-10)  Absolute Opioid dose > 100 mg morphine equivalents / day Ongoing litigation Mental / psychiatric disorder that may affect treatment Chronic generalized pain Pregnancy Hypersensitivity to local anesthetics Serious or unclear medical condition such as angina pectoris, severe vascular disorder, infection, malignancy disease, bleeding disorders Laminectomy in or above level for planned epidural access Spine surgery the last 3 months Relative
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.0,  Pulpotomy Children Children aged 5-8 years with at least two bilateral deep carious primary molars indicated for pulpotomy Children who are physically and mentally healthy without any known medical history of systemic conditions contraindicating pulp therapy Children who had "positive" or "definitely positive" behavioral ratings according to the Frankl behavior classification scale (Frankl, 1962) Children whose parents signed an informed consent for the child's participation in the study. Teeth Teeth were selected according to clinical and radiographic criteria. Clinically, the study included Teeth with restorable crowns Teeth with pathologic carious exposure of vital pulps Teeth with no tenderness to percussion, physiologic or pathologic mobility or any clinical evidence of pulp inflammation or degeneration such as history of swelling, pain or presence of sinus tract. Radiographically, the recruited teeth should have Normal radiographic appearance with healthy supporting tissues No pulp calcification  Any child complained of clinical signs such as pain, swelling, abnormal mobility, vertical or lateral tenderness to percussion was excluded from the study Radiographically, any child with signs of internal or external root resorption or periapical or inter-radicular pathology was omitted from the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 8.0-11.0,  Schistosomiasis School children, of public schools in villages of Saint Louis region (Senegal), female or male, 8 to 11 years old (inclusive) at the time of inclusion Residence in the area during the period of the study Free of obvious/severe health problems except schistosomiasis, as established by clinical examination Written informed consent to participate obtained from subject's parents or legal guardian Free of obvious/severe health problems except schistosomiasis, established by blood analysis, i.e. hematological exams, liver and renal function tests Treated with 40mg/kg Praziquantel (PZQ) before (W-2 to W-4 before the first injection) in case of infection with S. mansoni and S. haematobium Children of Group 1: not infected, no schistosomiasis history and living in area/village free of Sm and Sh transmission Children Groups 2 & 3: infected with mansoni or/and haematobium schistosomiasis  School child who does not respond to one of the Child under 20kg of body weight Vaccination within 90 days preceding the first dose of Sm14 vaccine candidate, or planned use during the study period Current or previous chronic administration (defined as more than 14 days) of immunosuppressive drugs or other immuno-modifying drugs Known hypersensitivity to any component in the Sm14 vaccine or history of allergic disease Knowledge of non-infectious chronic disease Known acute disease Other conditions which in opinion of the PI may potentially represent a danger for the patient to be enrolled
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis, Postmenopausal Women at least 50 years of age who are postmenopausal. Postmenopausal is defined as being amenorrheic for at a period of at least 12 months. 2. Diagnosis of osteoporosis by T score of < -2.5 at either lumbar spine or the hip/femoral neck, or osteopenia that qualifies for treatment by FRAX calculation (10-year risk of hip fracture > 3% and/or major osteoporotic fracture of > 20%). 3a. Subjects who have had chronic treatment of denosumab (as defined as > 1 year [at least 3 6-monthly injections]) or zoledronic acid (defined as ≥ 2 years [at least 2 annual injections]) . Note: At the time of treatment initiation, subjects must have met for on-label use (e.g. criterion 2 above). OR 3b. Subjects who are naïve to treatment with denosumab and/or zoledronic acid  Renal insufficiency, with glomerular filtration rate (GFR) < 35 ml/min. 2. Hypocalcemia within 6 months of study initiation. 3. Known hypersensitivity to denosumab or zoledronic acid. 4. Medications that could alter bone turnover including prednisone, anti-rheumatic medications, anti-metabolites (Cytoxan). Subjects who have been on stable doses of thyroid replacement or diabetes medications for more than 3 months are eligible. 5. Evidence of untreated oral cavities or oral infections. Preventative dental exams should be performed before starting denosumab or zoledronic acid. Subjects must avoid invasive dental procedures during treatment with denosumab or zoledronic acid
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Patients must have histologically confirmed prostate adenocarcinoma that is metastatic and castration resistant (mCRPC) At least 3 metastatic foci avid for PSMA-specific PET agent (CTT1057) uptake on Screening PSMA PET Has received docetaxol, ineligible for docetaxol, or refused docetaxol for the treatment of prostate cancer Has progression by the PCWG3 during or after treatment with either abiraterone or enzalutamide Male Age ≥ 18 years Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (see Appendix 2). Demonstrate adequate organ function  Has received previous treatment with radium-223 or another radiopharmaceutical within 3 months prior to first dose of CTT1403 Has received cabazitaxel for the treatment of mCRPC Has received previous treatment with a therapeutic targeting PSMA Has an additional active malignancy requiring therapy that may confound the assessment of the study endpoints Has clinically significant cardiovascular disease Has a history of untreated brain metastases Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days before CTT1403 administration Has known positive status for chronic hepatitis B or hepatitis C Known or suspected myelodysplastic syndrome Has any medical condition which in the opinion of the Investigator places the patient at an unacceptably high risk for toxicities
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-70.0,  Infection Patient age from 16 to 70 yrs old Patient needs surgical teeth extraction (subject tooth will be removed using osteotomy by motorised drill)  Patients refusing the preoperative dose of oral co-amoxiclav, and unwilling to take part  Patients who are allergic to co-amoxiclve, amoxicillin or metronidazole Patient are on warfarin medication
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Paget Disease Subject that participated in ZiPP Participant willing and able to consent and comply with the study protocol  Unable or unwilling to provide informed consent